TARRYTOWN, N.Y. and PARIS, April 26, 2019 /PRNewswire/ — * Praluent is the first PCSK9 inhibitor that has shown a meaningful reduction in death from any cause * Praluent treatment effect was observed in patients already receiving other lipid-lowering therapies, including maximally-tolerated statins Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Praluent® (alirocumab) to reduce…
On June 27th, 2018, the Centers for Medicare and Medicaid Services (CMS) announced that they are reconsidering the National Coverage Determination (NCD) for transcatheter aortic valve replacement (TAVR). A NCD is a nationwide policy on whether Medicare will pay for a particular item or service, and under what circumstances. The current NCD lays out requirements…
Dear ABC Members and Friends, Pharmaceutical CEOs testified before the Senate last month. Tomorrow, Pharmacy Benefit Managers (PBMs) will discuss drug pricing with the Senate Finance Committee. This committee has jurisdiction over Medicare Part D patient legislation. Leaders from Express Scripts, CVS Caremark, Humana, Optum, and Prime Therapeutics will discuss solutions, including HHS plans to…
The Association of Black Cardiologists issued a joint statement along with the Alliance for Aging Research, Heart Valve Voice US, and Mended Hearts in response to the Centers for Medicare and Medicaid Services’ proposed decision to cover Transcatheter Aortic Valve Replacement (TAVR) for the treatment of symptomatic aortic valve stenosis through Coverage with Evidence Development (CED). This…
FOR IMMEDIATE RELEASE Portland, OR, March 22, 2019 — Since opening shop in 2015, the mission statement for Classic Men Barbershop & Lounge is to cater to all people that are looking for upscale hair treatments and provide premium services to men and women of all ages. On April 6th, Classic Men is looking to set-up everyone…
Read “Sanofi’s 2019 Pricing Principles Report,” an update to the Pricing Principles established for 2018 which focuses on three pillars: basing prices on value, limiting price increases, and being transparent about those prices. Read the full report: